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Abstract
Coronary heart disease, stroke, diabetes mellitus, hypertension, cancer, depression schizophrenia,
Alzheimer's disease, and collagen vascular diseases are low-grade systemic inflammatory conditions
that are a severe burden on health care resources. Essential fatty acids (EFAs) and their
metabolites: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), gamma-linolenic acid
(GLA), dihomo-gamma-linolenic acid (DGLA), and arachidonic acid (AA) and their products:
prostaglandin E1, prostacyclin, lipoxins, resolvins, and protectins suppress inflammation, augment
healing, and are of benefit in the prevention and management of these conditions. Hence,
supplementation of EFAs could reduce burden of these disease(s).
Introduction
Coronary heart disease (CHD), stroke, diabetes mellitus,
hypertension, cancer, depression, schizophrenia, Alzhe-
imer's disease, and collagen vascular diseases are a severe
burden on the health care system throughout the world
[1]. The major determinants of these chronic diseases are
tobacco smoking, inadequate physical activity, unhealthy
diets, overweight/obesity, suboptimal levels of blood
pressure, cholesterol, and plasma glucose [2-4]. It was
estimated that a multidrug regimen comprising of a statin,
aspirin, and two blood-pressure lowering medicines
reduces about 17.9 million deaths from cardiovascular
diseases [4]. But, any strategy that prevents stroke, cancer
and other chronic diseases in addition to cardiovascular
diseases is expected to reduce the burden of chronic dis-
eases substantially. Low-grade systemic inflammation is
one of the characteristic features of CHD, stroke, diabetes
mellitus, hypertension, cancer, depression schizophrenia,
Alzheimer's disease, and collagen vascular diseases imply-
ing that prevention or suppression of inflammation
reduces burden of these diseases.
Low-grade systemic inflammation in chronic 
diseases
Plasma C-reactive protein (CRP), tumor necrosis factor-α
(TNF-α), and interleukin-6 (IL-6), markers of inflamma-
tion, levels are elevated in subjects with obesity, insulin
resistance, essential hypertension, type 2 diabetes, and
CHD [5-10], suggesting that low-grade systemic inflam-
mation occurs in them. Alzheimer's disease, depression,
and schizophrenia are also low-grade systemic inflamma-
tory conditions since, elevated levels of pro-inflammatory
cytokines occurs in the plasma and brains of these
patients [11,12].
Chronic inflammation is a major causative factor of
human malignancies. Pro-inflammatory cytokines influ-
ence tumor microenvironment and promote cell growth
and survival and angiogenesis such that tumor cell growth
is facilitated. Thus, immune system activation could be a
double edged sword: immune surveillance may check
tumor development whereas aberrant immune activation
promotes malignant growth [13,14].
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Low-grade systemic inflammatory conditions 
are also essential fatty acid deficient states
Essential fatty acids (EFAs): cis-linoleic acid (LA, 18:2, ω-
6) and α-linolenic acid (ALA, 18:3, ω-3) are important
constituents of all cell membranes and alter membrane
fluidity and thus, determine and influence the behaviour
of membrane-bound enzymes and receptors. EFAs are
essential and as are not synthesized in the body; have to
be obtained in diet [15,16]. LA is converted to γ-linolenic
acid (GLA, 18:3) by the enzyme Δ6 desaturase (d-6-d) and
GLA is elongated to form dihomo-GLA (DGLA, 20:3), the
precursor of the 1 series of prostaglandins (PGs). DGLA
can also be converted to arachidonic acid (AA, 20:4, ω-6)
by the enzyme Δ5 desaturase (d-5-d). AA forms the precur-
sor of 2 series of PGs, thromboxanes (TXs) and the 4 series
of leukotrienes (LTs). ALA is converted to eicosapentae-
noic acid (EPA, 20:5) by d-6-d and d-5-d. EPA forms the
precursor of the 3 series of PGs, TXs and the 5 series of LTs
and docosahexaenoic acid (DHA). LA, GLA, DGLA, AA,
ALA, EPA and DHA are all PUFAs, but only LA and ALA are
EFAs (see Figure 1 for metabolism of EFAs). Although the
terms EFAs and PUFAs are used interchangeably for the
sake of convenience it should be understood that all EFAs
are PUFAs but all PUFAs are not EFAs.
Most of the PGs, TXs, and LTs have pro-inflammatory
actions. AA, EPA and DHA also give rise to anti-inflamma-
tory molecules: lipoxins (LXs), resolvins, and protectins
(such as neuroprotectin D1). Thus, PUFAs form precur-
sors to both pro- and anti-inflammatory molecules and
the balance between these mutually antagonistic com-
pounds could determine the final outcome of the disease
process (see Figure 1). In addition, nitration of unsatu-
rated fatty acids occurs leading to the formation of nitrol-
ipids that stimulate smooth muscle relaxation, block
platelet activation, inhibit human neutrophil functions
and suppress inflammation [15,16]. These studies suggest
that PUFAs have important actions not only by them-
selves but also by giving raise to various biologically active
compounds.
EFAs/PUFAs play a significant role in collagen vascular
diseases, hypertension, diabetes mellitus, metabolic syn-
drome X, psoriasis, Alzheimer's disease, schizophrenia,
depression, CHD, atherosclerosis, and cancer [17-25]. In
all these conditions, plasma and tissue levels of GLA,
DGLA, AA, EPA, and DHA are significantly low compared
to normal suggesting that EFA/PUFA deficiency either pre-
disposes or initiates the onset of these diseases [5,7,10-
12,15-25]. EFAs/PUFAs play a significant role in such
diverse conditions due to their ability to modulate cell
membrane fluidity, possess second messenger action,
influence angiotensin converting and HMG-CoA reduct-
ase enzymes, serve as ligands for nuclear receptors PPARs
(peroxisome proliferator-activated receptors), LXR (liver X
receptor), FXR (Farnesol X receptor), HNF-4α (hepatocyte
nuclear factor-4α), enhance endothelial nitric oxide
(eNO) generation, suppress leukocyte activation and pro-
duction of pro-inflammatory cytokines IL-6 and TNF-α,
prevent platelet aggregation, and regulate telomere length
(reviewed in [26]). In addition, PUFAs form precursors to
potent anti-inflammatory molecules: lipoxins, resolvins,
and protectins that are essential to suppress inflammatory
process and enhance healing [15,16].
In this context, it is noteworthy that saturated fats, choles-
terol, trans-fatty acids, alcohol, adrenaline, and glucocor-
ticoids inhibit Δ6 and  Δ5 desaturases; pyridoxine, zinc,
nicotinic acid, and magnesium are co-factors for normal
Δ6 desaturase activity; whereas insulin activates Δ6 desatu-
rase; and diabetics, hypertensives, and those with hyperli-
pidemias have reduced Δ6 and  Δ5 desaturase (Δ6 >  Δ5)
activities [15,16]. The activity of Δ6 desaturase falls with
age. Oncogenic viruses including hepatitis C virus and
radiation inhibit Δ6 desaturase activity. Total fasting, pro-
tein deficiency, and a glucose-rich diet reduce, whereas
fat-free diet and partial caloric restriction enhance Δ6
desaturase activity. Activity of Δ6 and Δ5 desaturases are
regulated by sterol regulatory element binding protein-1
(SREBP-1) and peroxisome proliferator-activated recep-
tor-α (PPAR-α), two reciprocal transcription factors for
fatty acid metabolism, and some of their (SREBP-1 and
PPAR-α) lipogenic functions are brought about by their
action on PUFAs [27]. Interference with the metabolism
of EFAs by saturated fats, cholesterol and trans fats, glu-
cose, insulin deficiency, viruses, alcohol, and ageing
reduces the formation of GLA, DGLA, AA, EPA, and DHA
and their beneficial metabolites prostacyclin (PGI2), PGI3,
lipoxins, resolvins, and protectins that could account for
the initiation and progression of atherosclerosis, persist-
ence of inflammation, CHD and failure of the healing
process [15,16,19,24].
PUFAs have anti-bacterial, anti-viral, anti-fungal, 
anti-parasitic actions
LA, ALA, and AA have bacteriostatic effect on both gram-
positive and gram-negative bacteria [28]. Both LA and AA
can inactivate animal herpes, influenza, Sendai, and Sind-
bis virus within minutes of contact [29].
LA, AA, EPA, and DHA induced death of Plasmodium both
in vitro and in vivo [30-32]. An analog of myristic acid
(14:0) showed selective toxicity to African Trypanosomes
[33]. Prostaglandin E1 (PGE1) and PGA, derived from
DGLA, AA, and EPA inhibited viral replication [34,35].
These results suggest that PUFAs function as endogenous
anti-bacterial, anti-parasitic, and anti-viral molecules
[36,37]. PUFAs augment the anti-bacterial actions of syn-
thetic antibiotics against drug-resistant bacteria [38].
There is evidence to suggest that PUFAs can inactivate HIVLipids in Health and Disease 2008, 7:9 http://www.lipidworld.com/content/7/1/9
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Scheme showing metabolism of essential fatty acids and factors that modulate the formation of their metabolites and their  actions Figure 1
Scheme showing metabolism of essential fatty acids and factors that modulate the formation of their metabo-
lites and their actions. Pro-inflammatory molecules include various PGs, LTs, TXs, and cytokines. For further details see 
text. NO = Endothelial Nitric oxide. Green line: Indicates prevention or suppression of disease and augmentation of healing 
process and inhibition of pro-inflammatory events or production of pro-inflammatory molecules. Red line: Indicates initiation 
or progression of disease, inflammatory process or augmentation of production of pro-inflammatory molecules. Double arrow: 
Indicates interaction between these molecules or feedback regulation. Eicosanoids formed from EPA are generally less inflam-
matory in nature compared to those formed from AA. Eicosanoids includes PGs, LTs, TXs, EETs, and HETEs.
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(human immunodeficiency virus), an enveloped virus,
and thus, is of benefit in AIDS (acquired immunodefi-
ciency syndrome) [39,40]. Patients with AIDS and intra-
venous drug abusers have low plasma phospholipid
DGLA, AA and DHA concentrations that could favour the
onset and development of AIDS [41,42]. Lymphocytes
and macrophages contain significant amounts of PUFAs
and release them on appropriate stimulation. PUFAs stim-
ulate NADPH-dependent superoxide production by mac-
rophages, neutrophils and lymphocytes that has
bactericidal action [43].
AA, DHA, and EPA exert anti-HCV (hepatitis C virus)
activities at physiologically relevant concentrations.
Strong synergistic anti-HCV effect was observed when AA
was combined with IFN-α (interferon-α) [44-46]. The
anti-HCV action of PUFAs is due to the formation of sig-
nificant amounts of lipid peroxides. Previously, I
observed that PUFA-induced tumoricidal action is also
due to increased formation of lipid peroxides and free rad-
ical generation [47]. Thus, PUFAs have anti-bacterial, anti-
fungal, anti-viral, anti-parasitic and tumoricidal actions.
Hypothesis
It is evident from the preceding discussion that EFAs/
PUFAs are not only naturally occurring endogenous sub-
stances present in almost all tissues and essential compo-
nents of all mammalian cells but also useful in the
prevention and treatment of low-grade systemic inflam-
matory conditions: atherosclerosis, CHD, stroke, diabetes
mellitus, hypertension, cancer, depression, schizophre-
nia, Alzheimer's disease, and collagen vascular diseases if
they are present in adequate amounts in various target tis-
sues [15-26]; and function as endogenous anti-biotic-like
molecules [36,37,44]. EFAs/PUFAs have aspirin-like
action, inhibit of HMG-CoA and ACE enzymes, and pos-
sess diuretic, anti-hypertensive, and β-blocker-like
actions, which suggests that they (PUFAs) function as
endogenous "polypill" and thus, prevent cardiovascular
mortality and morbidity [48].
Dietary intake of PUFAs (especially ω-3) from infancy
reduced the risk for type 1 diabetes [49] confirming previ-
ous animal studies that PUFAs prevent chemical-induced
diabetes [22,23]. Increasing concentrations of ω-6 DGLA
and AA in breast milk reduced the risk of mother-to-child
transmission of HIV [50] suggesting that PUFAs have anti-
HIV actions [39,40]. Since many low-grade systemic
inflammatory conditions may have their origins in the
perinatal period [18], I propose that PUFAs be given to
pregnant women and lactating mothers and to children
from infancy throughout life to reduce the burden of both
infectious and non-infectious diseases.
This hypothesis can be tested by studying the effect of sup-
plementation of ω-3 and ω-6 fatty acids (in different com-
binations and doses) in animal models of various human
diseases. It is envisaged in this hypothesis that the plasma
and tissue concentrations of various PUFAs and their ben-
eficial metabolites such as PGI2, PGE1, lipoxins, resolvins,
and protectins will be lower in various low-grade systemic
inflammatory conditions compared to normal. This
hypothesis implies that in subjects who have lower nor-
mal levels and those who are marginally deficient in
PUFAs are more likely to develop HCV, HIV, malaria, and
bacterial infections. If this hypothesis is true, it indicates
that those who fail to produce adequate amounts of lipox-
ins, resolvins, and protectins are less likely to recover from
these diseases in time. Since, various PUFAs can be
obtained from diet or supplemented from external
sources; it will be interesting to study the therapeutic ben-
efits of various ω-3 and ω-6 fatty acids in the diseases that
have been enumerated above. It is important to study
which type (ω-3, ω-6 or both) of fatty acids and in what
combination or ratio and which form (oral or parenteral)
are most suited to suppress or give relief from various dis-
eases. It is relevant to study whether suitable synthetic
analogues of various PUFAs can be developed for their
possible therapeutic use in various diseases. Since most of
the low-grade systemic inflammatory conditions have
their origin in the perinatal period and childhood, it is
important that studies are performed wherein PUFAs are
given from infancy and wherever possible to the mother
during pregnancy and lactation till adult age to know
whether such long (sometimes even lifelong) term sup-
plementation is necessary to suppress or postpone the
development of the disease or at least decrease the severity
of the disease in the event it occurs. Since PUFAs are rela-
tively safe even when taken for long periods of time, such
intervention studies in humans are not difficult. Prelimi-
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